Promises and pitfalls of anti-angiogenic therapy in clinical trials

Trends in Molecular Medicine

Volumn 9, Issue 2, 2003, Pages 53-58

  McCartya, Marya F ^a   Liu, Wenbiao ^a   Fan, Fan ^a   Parikh, Alex ^a   Reimuth, Niels ^a   Stoeltzing, Oliver ^a   Ellis, Lee M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5,6,7,13 TETRAHYDRO 12 (3 HYDROXYPROPYL) 9 ISOPROPOXYMETHYLINDENO[2,1 A]PYRROLO[3,4 C]CARBAZOL 5(12H) ONE DIMETHYLGLYCINE ESTER; ALPHA INTERFERON; ANGIOARRESTIN; ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; ANGIOSTATIN; ANGIOZYME; ANTITHROMBIN; BETA INTERFERON; BEVACIZUMAB; CILENGITIDE; CNTO 95; COMBRETASTATIN A4; ENDOSTATIN; GAMMA INTERFERON; N ACETYLCOLCHINOL PHOSPHATE; N ACETYLSARCOSYLGLYCYLVALYL DEXTRO ALLOISOLEUCYLTHREONYLNORVALYLISOLEUCYLARGINYLPROLINE ETHYLAMIDE; SEMAXANIB; SUNITINIB; THALIDOMIDE; THROMBOCYTE FACTOR 4; THROMBOSPONDIN 1; THROMBOSPONDIN 2; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TUMSTATIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VASCULOSTATIN; VATALANIB; VITAXIN II;

ANGIOGENESIS; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DATA ANALYSIS; DRUG EFFICACY; DRUG TARGETING; HUMAN; NONHUMAN; PHENOTYPE; REVIEW;

EID: 0037294613     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4914(03)00002-9     Document Type: Review

References (60)

1. Folkman, J. (1992) The role of angiogenesis in tumor growth. Semin. Cancer Biol. 3, 65-71
2. Bouck, N. (1990) Tumor angiogenesis: the role of oncogenes and tumor suppressor genes. Cancer Cells 2, 179-185
3. Ellis, L.M. et al. (2001) Role of angiogenesis inhibitors in cancer treatment. Oncology 15 (Suppl. 8), 39-46
4. Dvorak, H.F. et al. (1995) Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Pathol. 146, 1029-1039
5. Matsumoto, T. and Claesson-Welsh, L. (2001) VEGF receptor signal transduction. Sci. STKE 112, RE21
6. Stimpfl, M. et al. (2002) Vascular endothelial growth factor splice variants and their prognostic value in breast and ovarian cancer. Clin. Cancer Res. 8, 2253-2259
7. Luttun, A. et al. (2002) Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Fit1. Nat. Med. 8, 831-840
8. Wu, Y. et al. (2002) Monoclonal antibody against VEGFR1 inhibits fit-1 positive breast tumor growth by a dual mechanism involving anti-endothelial and anti-tumor cell growth activities. Proceedings of the American Association for Cancer Research, pp. 43, American Association for Cancer Research
9. He, Y. et al. (2002) Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J. Natl. Cancer Inst. 94, 819-825
10. Soker, S. et al. (1998) Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92, 735-745
11. Betsholtz, C. et al. (2001) Developmental roles of platelet-derived growth factors. Bioessays 23, 494-507
12. Hsu, S. et al. (1995) Platelet-derived growth factor-B increases colon cancer cell growth in vivo by a paracrine effect. J. Cell. Physiol. 165, 239-245
13. Reinmuth, N. et al. (2001) Induction of VEGF in perivascular cells defines a potential paracrine mechanism for endothelial cell survival. FASEB J. 15, 1239-1241
14. Hynes, R.O. (1992) Integrins: versatility, modulation, and signaling in cell adhesion. Cell 69, 11-25
15. Meredith, J.E. Jr et al. (1993) The extracellular matrix as a cell survival factor. Mol. Biol. Cell 4, 953-961
16. 3 blocks human breast cancer growth and angiogenesis in human skin. J. Clin. Invest. 96, 1815-1822
17. v integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J. Clin. Invest. 103, 1227-1230
18. Reinmuth, N. et al. (2001) Endothelial survival factors as targets for antineoplastic therapy. Cancer J. 7 (Suppl. 3), S109-S119
19. Rosen, L.S. (2002) Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers. Cancer Control 9, 36-44
20. O'Reilly, M.S. et al. (1994) Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79, 315-328
21. O'Reilly, M.S. et al. (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88, 277-285
22. Lee, S.J. et al. (2002) Endostatin binds to the catalytic domain of matrix metalloproteinase-2. FEBS Lett. 519, 147-152
23. Urbich, C. et al. (2002) Dephosphorylation of endothelial nitric oxide synthase contributes to the anti-angiogenic effects of endostatin. FASEB J. 16, 706-708
24. Dixelius, J. et al. (2002) Endostatin regulates endothelial cell adhesion and cytoskeletal organization. Cancer Res. 62, 1944-1947
25. Moser, T.L. et al. (1999) Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc. Natl. Acad. Sci. U. S. A. 96, 2811-2816
26. Baenziger, N.L. et al. (1972) Isolation and properties of a thrombin-sensitive protein of human platelets. J. Biol. Chem. 247, 2723-2731
27. Qian, X. and Tuszynski, G.P. (1996) Expression of thrombospondin-1 in cancer: a role in tumor progression. Proc. Soc. Exp. Biol. Med. 212, 199-207
28. Bloemendal, H.J. et al. (1999) New strategies in anti-vascular cancer therapy. Eur. J. Clin. Invest. 29, 802-809
29. Hood, J.D. et al. (2002) Tumor regression by targeted gene delivery to the neovasculature. Science 296, 2404-2407
30. Blakey, D.C. et al. (2002) Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin. Cancer Res. 8, 1974-1983
31. DeVore, R.F. et al. (2000) A randomized phase II trial comparing Rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with Stage IIIB/IV NSCLC. In 2000 Annual Meeting of the American Society of Clinical Oncology, A1896, American Society of Clinical Oncology
32. Bergsland, E. et al. (2000) A randomized phase II trial comparing rhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus 5-fluorouracil/leucovorin (FU/LV) to FU/LV alone in patients with metastatic colorectal cancer. In 2000 Annual Meeting of the American Society of Clinical Oncology, A242, American Society of Clinical Oncology
33. Yang, J.C. et al. (2002) A randomized double-blind placebo-controlled trial of bevacizuman (anti-VEGf antibody) demonstrating a prolongation in time to progression in patients with metastatic renal cancer. In 2002 Annual Meeting of the American Society of Clinical Oncology, A15, American Society of Clinical Oncology
34. Shaheen, R.M. et al. (1999) Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res. 59, 5412-5416
35. Ribatti, D. et al. (2002) Endothelial cell heterogeneity and organ specificity. J. Hematother. Stem Cell Res. 11, 81-90
36. Rajotte, D. et al. (1998) Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display. J. Clin. Invest. 102, 430-437
37. Benjamin, L.E. et al. (1999) Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J. Clin. Invest. 103, 159-165
38. Eskens, F.A. and Verweij, J. (2000) Clinical studies in the development of new anticancer agents exhibiting growth inhibition in models: facing the challenge of a proper study design. Crit. Rev. Oncol. Hematol. 34, 83-88
39. Kuenen, B.C. et al. (2002) Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J. Clin. Oncol. 20, 1657-1667
40. Fidler, I.J. (2000) Angiogenesis and cancer metastasis. Cancer J. 6 (Suppl. 2), S134-S141
41. Yu, J.L. et al. (2002) Effect of p53 status on tumor response to antiangiogenic therapy. Science 295, 1526-1528
42. Yang, H. and Kaelin, W.G. Jr (2001) Molecular pathogenesis of the von Hippel-Lindau hereditary cancer syndrome: implications for oxygen sensing. Cell Growth Differ. 12, 447-455
43. Semenza, G.L. (2002) HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol. Med. 8 (Suppl. 4), S62-S67
44. Yano, S. et al. (2000) Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells. Am. J. Pathol. 157, 1893-1903
45. Xu, L. et al. (2000) Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Int. J. Oncol. 16, 445-454
46. Zebrowski, B.K. et al. (1999) Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions. Clin. Cancer Res. 5, 3364-3368
47. Arbiser, J.L. et al. (1997) Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc. Natl. Acad. Sci. U. S. A. 94, 861-866
48. Rak, J. et al. (1995) Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res. 55, 4575-4580
49. Iberg, N. et al. (1989) Purification of 18- and 22-kDa forms of basic fibroblast growth factor from rat cells transformed by the ras oncogene. J. Biol. Chem. 264, 19951-19955
50. Zhang, X. et al. (2001) Regulation of vascular endothelial growth factor by the Wnt and K-ras pathways in colonic neoplasia. Cancer Res. 61, 6050-6054
51. Przybyszewska, M. et al. (1998) Angiogenesis induced by urothelial cells (HCV-29) and their v-ras and v-raf transfectants. Cancer Lett. 131,157-161
52. Fleming, R.Y. et al. (1997) Regulation of vascular endothelial growth factor expression in human colon carcinoma cells by activity of src kinase. Surgery 122, 501-507
53. Ellis, L.M. et al. (1998) Down-regulation of vascular endothelial growth factor in a human colon carcinoma cell line transfected with an antisense expression vector specific for c-src. J. Biol. Chem. 273, 1052-1057
54. Huang, J. and Kontos, C.D. (2002) PTEN modulates vascular endothelial growth factor-mediated signaling and angiogenic effects. J. Biol. Chem. 277, 10760-10766
55. Dameron, K.M. et al. (1994) Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265, 1582-1584
56. Mukhopadhyay, D. et al. (1997) The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity. Mol. Cell. Biol. 17, 5629-5639
57. Lopez-Ocejo, O. et al. (2000) Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner. Oncogene 19, 4611-4620
58. Kerbel, R.S. et al. (2000) 'Accidental' anti-angiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples. Eur. J. Cancer 36, 1248-1257
59. Izumi, Y. et al. (2002) Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 416, 279-280
60. Kraemer, M. et al. (1999) Rat embryo fibroblasts transformed by c-Jun display highly metastatic and angiogenic activities in vivo and deregulate gene expression of both angiogenic and antiangiogenic factors. Cell Growth Differ. 10, 193-200